Metraipolis › archive › dc_a2bb7292b4fe

Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis — Europe PMC PMID:42261260

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42261260
DOI
10.1093/rheumatology/keag289
License (as archived)
solo-consultazione
Archived
2026-10-31T23:49:09.926Z
SHA-256 of the archived text
7b56deae2ea4dec511c357ad0247f08b25bf4aa1d7f8b2780b1ad979c837b204
Stable URL of this page
https://metraipolis.com/documento/dc_a2bb7292b4fe

How to cite

Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis — Europe PMC PMID:42261260 — Europe PMC (en), https://europepmc.org/article/MED/42261260 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a2bb7292b4fe (Metraipolis archive dc_a2bb7292b4fe, sha256 7b56deae2ea4dec511c357ad0247f08b25bf4aa1d7f8b2780b1ad979c837b204)
BibTeX
@misc{dca2bb7292b4fe,
  title = {Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis — Europe PMC PMID:42261260},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42261260},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a2bb7292b4fe; sha256 7b56deae2ea4dec511c357ad0247f08b25bf4aa1d7f8b2780b1ad979c837b204},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42261260. Agents can read the archived copy with the MCP tool read_document.